Paul Axtell Bunn, JR
Physician in Denver, CO

6388054, May 14, 2002

Aug 19, 1999

09/378019

John M. Stewart - Denver CO 80210
Daniel C. F. Chan - Denver CO 80237
Lajos Gera - Denver CO 80237
Eunice York - Englewood CO 80110
Paul Bunn - Evergreen CO 80439

C07K 700

530314, 530328, 530329, 530330, 530332, 530402, 530815, 530816

The present invention provides compounds useful to inhibit tumor growth and to induce apoptosis. In general, the anti-cancer agents (ACA) are described by the formula: wherein X is a linker group having 2-5 functional groups or is absent, n=1, and ACA is selected from the group consisting of Formula II, Formula III, Formula IV, Formula V, and Formula VI, as described herein. Other compounds described herein are defined by the Formula VII, as described herein.

2012017, Jul 12, 2012

Mar 12, 2012

13/418004

Paul A. BUNN - Evergreen CO, US
Christopher D. COLDREN - Denver CO, US
Wilbur A. FRANKLIN - Denver CO, US
Mark W. GERACI - Aurora CO, US
Barbara A. HELFRICH - Lakewood CO, US
Fred R. HIRSCH - Denver CO, US
Razvan LAPADAT - Denver CO, US
Michio SUGITA - Centennial CO, US
Samir E. WITTA - Greenwood Village CO, US

A61K 39/395, A61K 31/517, A61P 35/00, C40B 30/00, G01N 33/566, G01N 21/64, G01N 21/76, G01N 27/62, A61K 31/5377, C12Q 1/02

4241331, 4241421, 5142345, 5142664, 435 29, 435 723, 506 7

Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.

2008009, Apr 17, 2008

May 26, 2005

11/568760

Marileila Varella Garcia - Greenwood Village CO, US
Paul A. Bunn - Evergreen CO, US
Federico Cappuzzo - Bologna, IT
Wilbur A. Franklin - Denver CO, US
Fred R. Hirsch - Denver CO, US

THE REGENTS OF THE UNIVERSITY OF COLORADO - Boulder CO

C12Q 1/68, C12Q 1/00, G01N 33/483

435 6, 435 4, 435 405

Disclosed are biomarkers, methods and assay kits for the identification of cancer patients who are predicted to benefit, or not to benefit, from the therapeutic administration of an epidermal growth factor receptor (EGFR) inhibitor. The biomarkers of the present invention include detection of EGFR and HER 2 gene amplification and polysomy, EGFR protein expression, EGFR mutations, phosphorylated Akt protein expression, and various combinations of such biomarkers, as well as the combination of these biomarkers with mutations in the tyrosine kinase domain of the EGFR gene. Increased EGFR gene copy number, increased HER2 gene copy number, increased EGFR, protein expression, activated AKT protein expression (phosphorylated AKT) and EGFR mutations are all associated with better outcome for cancer patients treated with EGFR inhibitors. The invention provides a diagnostic paradigm based on each of these tests and combinations of these tests to select cancer patients who will benefit from EGFR inhibitor therapy, as well as a diagnostic paradigm to select cancer patients who will not benefit from EGFR inhibitor therapy.

6048550, Apr 11, 2000

Oct 2, 1997

8/942758

Daniel C. F. Chan - Denver CO
Paul Bunn - Evergreen CO
Dmitri Kirpotin - San Francisco CA

A61K 914

424497

The present invention comprises a material and a method of its preparation. The material may be described as hydrophilic microparticles, comprising a cluster of organic substance with a layer of polyelectrolyte on its surface. The present invention establishes an improved method for preparing aqueous colloidal dispersions of water-insoluble organic substances using polyionic hydrophilic polymers by which the stability of the suspension is maintained after removal of the stabilizing and/or solubilizing medium of the drug. This improved method can be utilized to formulate a variety of water-insoluble organic substances.

5411730, May 2, 1995

Jul 20, 1993

8/094790

Dmitri Kirpotin - Denver CO
Daniel C. F. Chan - Denver CO
Paul A. Bunn - Evergreen CO

Research Corporation Technologies, Inc. - Tucson AZ

A61B 5055, A61K 31715

424322

Superparamagnetic particles are provided for medical applications including hyperthermia techniques, localized heating and tissue-specific release of therapeutic agents, and magnetic resonance imaging contrast enhancement, comprising superparamagnetic iron oxide and a polymer such as dextran at a ratio of about 0. 5 to 0. 1 w/w of polymer to iron. The particles display at least one of the following magnetic properties: (a) specific power absorption rate greater than 300 w/g Fe; (b) initial magnetic susceptibility greater than 0. 7 EMU/g Fe/Gauss; and (c) magnetic moment greater than 10. sup. -15 erg/Gauss.

2012014, Jun 7, 2012

Jul 23, 2008

12/670053

Samir E. Witta - Greenwood Village CO, US
Paul A. Bunn - Evergreen CO, US
Harry A. Drabkin - Denver CO, US
Robert M. Gemmill - Centennial CO, US
Daniel Chan - Denver CO, US

A61K 39/395, A61P 35/00, A61K 31/404, A61K 31/343, A61K 31/496, A61K 31/517, A61K 31/4406, A61K 38/12

4241341, 514357, 514 199, 514469, 51425218, 51426624, 514414, 4241741, 4241331, 514 194

Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity.

7071168, Jul 4, 2006

Dec 28, 2001

10/035662

John M. Stewart - Denver CO, US
Daniel C. F. Chan - Denver CO, US
Lajos Gera - Denver CO, US
Eunice York - Englewood CO, US
Paul Bunn - Evergreen CO, US

The Regents of the University of Colorado - CO

A61K 38/00, A61K 49/00

514 19, 435106, 435117, 435 723, 424 91, 530300, 530314, 530333, 530402, 562433

The present invention provides compounds useful to inhibit tumor growth and to induce apoptosis. In general, the anti-cancer agents (ACA) are described by the formula: [ACA]-X[Formula I] wherein X is a linker group having 2–5 functional groups or is absent, n=1, and ACA is selected from the group consisting of Formula II, Formula III, Formula IV, Formula V, and Formula VI, as described herein. Other compounds described herein are defined by the Formula VII, as described herein.

8575170, Nov 5, 2013

Feb 25, 2011

13/035834

Lajos Gera - Denver CO, US
Daniel C. Chan - Denver CO, US
Robert S. Hodges - Denver CO, US
Paul A. Bunn - Denver CO, US

The Regents of the Unversity of Colorado, a body corporate - Denver CO

A61K 31/495, A61K 31/4453, C07D 295/15

51425212, 514331, 544400, 546234

Flurbiprofen analog compounds having an amino acid derivatized at the flurbiprofen alkanoic acid carboxyl group and terminating at an ester or amide group are effective in inhibiting cancer cells in vitro and inhibiting the growth of cancers in viva. The compounds and pharmaceutical compositions containing them are particularly useful for the treatment of lung, pancreatic and head and neck cancers.